Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function
about
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesityAdverse Effects of GLP-1 Receptor AgonistsThe Effect of Microbiota and the Immune System on the Development and Organization of the Enteric Nervous SystemLiraglutide and obesity: a review of the data so far.Three ileus cases associated with the use of dipeptidyl peptidase-4 inhibitors in diabetic patientsDrug-drug interactions in pharmacologic management of gastroparesis.A Transcriptome-Led Exploration of Molecular Mechanisms Regulating Somatostatin-Producing D-Cells in the Gastric Epithelium.Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and PharmacodynamicsGLP-1 receptor is expressed in human stomach mucosa: analysis of its cellular association and distribution within gastric glands.Effects of glucagon-like peptide-1 receptor agonists on renal functionReview of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass.Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.Novel insights into the effects of diabetes on gastric motility.GLP-1 based therapies: clinical implications for gastroenterologists.Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database.The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.Exenatide alters absorption of hydrocortisone in a diabetic patient with panhypopituitarism: iatrogenic adrenal insufficiency.Should Roux-en-Y gastric bypass biliopancreatic limb length be tailored to achieve improved diabetes outcomes?The stimulation of GLP-1 secretion and delivery of GLP-1 agonists via nanostructured lipid carriers.MRI assessment of the postprandial gastrointestinal motility and peptide response in healthy humans.Microbiome, Immunomodulation, and the Neuronal System.Role of Gut Microbiota-Gut Hormone Axis in the Pathophysiology of Functional Gastrointestinal Disorders.Dipeptidyl peptidase-4 inhibitors have adverse effects for the proliferation of human T cells
P2860
Q26765609-D91784B8-27BA-45C1-9491-C037C222D26EQ26801346-633E93AF-9772-4110-96F5-E0E73FE0DE6BQ28072096-8E8D5254-45E4-4F8B-810B-88C85D2AC4C1Q30924982-3B7B6873-5B53-4E96-8794-25A9013CE3D4Q33607811-1526F4EB-0901-4829-8211-54ECCA942968Q34480053-06B42A99-A824-4240-BB9C-4CACFE93F4FDQ36164350-79667901-6120-4E29-8A15-CE2035B8EE4CQ36302662-7B571B09-3ECD-4746-87C3-EC6A7AC8DFD1Q36924102-069F7772-44C2-4C08-8D41-8FF460EB6B75Q37122842-3E48DE41-C2F3-4292-A80F-03708AA15CD1Q37232679-BFF60A19-E30C-43F5-8DCA-213FD857AA19Q37340223-EA92F3A0-F021-4E6C-B014-F77799B641DEQ37670181-BD531DE4-1892-475B-A92A-4355E5B359EBQ38616170-0F6B1D2D-0FB8-4480-9A29-935DCA362914Q38662831-3DE4FFDD-3D5C-4DDF-AB31-92BF020C565DQ38703292-F9C8715D-532D-4BD3-B4ED-DF0539B2FA77Q38758454-4D02AEDA-4B3C-4C78-BE2C-D687AB5FD1A1Q38820260-23690346-51A0-4C8E-B81A-FDDC02378724Q42419419-D389754D-5504-47F3-B5B8-0A4F7ADB675EQ47196646-2D669B9A-DDF2-4789-AB34-C8A6521337B3Q47318926-EF82B38D-48D5-43B9-BD40-FC082D2F86CDQ47907528-48927EB2-5EEA-4AEE-A9DC-D0108E0F1F19Q48291240-39E66CF5-34CC-44CF-8CEF-24C9846082F6Q55527145-BBC9758C-6481-40D5-931F-69FFD148084AQ57125138-AEAD6E1E-2D86-4212-8865-466BCCD2882F
P2860
Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function
@en
Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function
@nl
type
label
Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function
@en
Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function
@nl
prefLabel
Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function
@en
Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function
@nl
P2093
P2860
P921
P356
P1476
Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function
@en
P2093
Chinmay S Marathe
Christopher K Rayner
Michael Horowitz
P2860
P304
P356
10.1155/2011/279530
P5008
P577
2011-06-22T00:00:00Z